CJC-1295 Without DAC is a synthetic growth hormone-releasing hormone (GHRH) analogue peptide widely adopted in endocrinology and growth axis related preclinical laboratory research. Unlike the DAC conjugated version, this variant removes the drug affinity complex (DAC) modification, resulting in a shorter half-life and more controllable pharmacokinetic profile in research models. It works by binding to the GHRH receptor located on pituitary somatotroph cells, stimulating the release of endogenous growth hormone in a pulsatile pattern, while also elevating IGF-1 levels as a downstream biomarker for research observation.

In vitro cellular experiments, this peptide is commonly used for GHRH receptor binding affinity testing, intracellular cAMP signaling detection, and pituitary cell secretion function studies. In animal research models, scientists utilize it to investigate the regulation of growth hormone secretion, body composition changes, muscle tissue development, as well as the interplay between somatotropic axis and metabolic homeostasis. It is a valuable research tool for exploring peptide structure-activity relationships, comparing the pharmacology difference between conjugated and non-conjugated GHRH analogues, and studying the feedback regulation mechanism of the hypothalamic-pituitary-growth axis. Related research also covers its influences on adipose tissue turnover, cellular proliferation and tissue repair biomarkers.

This peptide is produced through mature solid-phase peptide synthesis technology. Crude peptide material is processed with multiple cycles of reversed-phase HPLC purification to eliminate truncated peptide fragments, deamidated impurities, oxidized by-products and trace residual organic solvents. Each batch undergoes comprehensive quality control testing and comes with complete COA certification documents. The detection scope contains HPLC purity profiling, mass spectrometry molecular weight verification, moisture content measurement, residual solvent analysis, endotoxin test and microbial limit inspection, to guarantee low impurity levels and stable quality between different batches.

The lyophilized powder formulation greatly reduces the risk of peptide hydrolysis and degradation, providing dependable stability for cross-border international shipment and long-term frozen preservation. It supports a broad range of laboratory research applications, including in vitro pituitary cell culture assays, receptor binding and signal transduction analysis, in vivo animal endocrine model evaluation, peptide solubility and stability screening, and comparative pharmacological research of GHRH analogues.